



Visiting Professors

A case-based discussion on the management of prostate cancer

CLINICAL INVESTIGATOR

Matthew R Smith, MD, PhD

MODERATOR

Neil Love, MD

CONSULTING ONCOLOGIST

Stacey B Leibowitz, MD

Featuring a clinical investigator's perspective on a day spent visiting patients with prostate cancer in the clinic of a community-based oncologist



Subscribe to Podcasts or download MP3s of this program at ResearchToPractice.com/VPP111

From the publishers of:

Prostate Cancer™
UPDATE



Visiting Professors: A case-based discussion on the management of prostate cancer

OVERVIEW OF ACTIVITY

An estimated 220,000 new cases of prostate cancer are diagnosed yearly in the United States and account for approximately one third of new cancer cases among men. Published results from clinical trials lead to the emergence of new local and systemic therapeutic approaches, along with changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing urologist, radiation oncologist and medical oncologist must be well informed of these advances. To provide clinicians with therapeutic strategies to address the disparate needs of patients with prostate cancer, the *Visiting Professors* audio series employs an innovative case-based approach that unites the perspectives of leading prostate cancer investigators and community oncologists as they explore the intricacies of making treatment decisions. Upon completion of this CME activity, urologic oncology physicians should be able to formulate an up-to-date and more complete approach to the care of patients with prostate cancer.

LEARNING OBJECTIVES

- Use case-based learning, innovative communication strategies and shared clinical insight to provide comprehensive and compassionate oncology care.
- Develop a rational evidence-based approach to the use of bone-targeted therapies for patients with early and advanced-stage prostate cancer.
- Counsel patients with metastatic castration-resistant prostate cancer (mCRPC) about the effects of docetaxel and cabazitaxel on quality and quantity of life.
- Recall existing and emerging research information demonstrating the efficacy and tolerability of abiraterone acetate for patients with chemotherapy-pretreated CRPC, and use this information to guide treatment.
- Compare and contrast the efficacy, safety and tolerability of evidence-based chemotherapy and immunotherapy for patients with mCRPC.
- Evaluate symptoms, tumor burden and pace of disease, and factor these into the integration of sipuleucel-T in the treatment algorithm for mCRPC.
- Synthesize the emerging data and active research evaluating novel agents — including tyrosine kinase inhibitors, radiopharmaceuticals, androgen biosynthesis inhibitors and antiandrogens — in the setting of advanced prostate cancer, and discuss the biologic basis for their clinical activity.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 1.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the CD, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located in the back of this booklet or on our website at ResearchToPractice.com/VPP111/CME.

This activity is supported by educational grants from Amgen Inc, Astellas Pharma Global Development Inc/Medivation Inc, Bayer HealthCare Pharmaceuticals, Dendreon Corporation and Sanofi.

Last review date: December 2011; Release date: December 2011; Expiration date: December 2012

CME INFORMATION

CLINICAL INVESTIGATOR



Matthew R Smith, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Director, Genitourinary
Malignancies Program
Massachusetts General Hospital
Boston, Massachusetts

CONSULTING ONCOLOGIST



Stacey B Leibowitz, MD
Hematology Oncology Associates
of Northern NJ
Morristown, New Jersey

MODERATOR



Neil Love, MD
Research To Practice
Miami, Florida

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — **Dr Leibowitz** had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: **Dr Smith** — *Consulting Agreement:* Amgen Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Sanofi, Seattle Genetics and Teva Pharmaceuticals.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

QUESTIONS (PLEASE CIRCLE ANSWER):

- 1. In the COU-AA-301 pivotal study abiraterone prolonged overall survival compared to placebo in patients with mCRPC that progressed on docetaxel.**
 - a. True
 - b. False
- 2. Which of the following bone-targeted treatments was superior in reducing skeletal-related events in a Phase III study in patients with mCRPC?**
 - a. Zoledronic acid
 - b. Denosumab
 - c. Neither
- 3. Large studies in men with prostate cancer have demonstrated that denosumab is not associated with an increased risk of osteonecrosis of the jaw.**
 - a. True
 - b. False
- 4. Which of the following has a similar mechanism of action to abiraterone?**
 - a. Bicalutamide
 - b. MDV3100
 - c. TAK-700
- 5. Which of the following were commonly observed clinically significant adverse events with cabazitaxel/prednisone in the Phase III study for men with mCRPC progressing after docetaxel?**
 - a. Neutropenia
 - b. Diarrhea
 - c. Fatigue
 - d. All of the above
- 6. Sipuleucel-T treatment results in a high rate of objective tumor regression among patients with advanced prostate cancer.**
 - a. True
 - b. False
- 7. In a Phase III study denosumab prolonged bone metastasis-free survival in men with CRPC.**
 - a. True
 - b. False
- 8. Which of the following were observed in a study of cabozantinib (XL184) versus placebo in men with progressive, measurable mCRPC?**
 - a. High rates of bone-scan resolution
 - b. High rates of pain relief
 - c. Both a and b
 - d. Neither a nor b
- 9. In a Phase III study of patients with CRPC and bone metastases, treatment with radium-223 chloride (Alpharadin®) resulted in an improvement in overall survival.**
 - a. True
 - b. False
- 10. In the Phase III IMPACT study, sipuleucel-T resulted in a significant improvement in survival compared to placebo in men with _____ mCRPC.**
 - a. Symptomatic
 - b. Asymptomatic
 - c. Both a and b

Educational Assessment and Credit Form
Visiting Professors Prostate Cancer, Issue 1, 2011

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

PART 1 — Please tell us about your experience with this educational activity

How would you characterize your level of knowledge on the following topics?

	4 = Excellent	3 = Good	2 = Adequate	1 = Suboptimal
	BEFORE		AFTER	
IMPACT study results and integration of sipuleucel-T into the treatment of mCRPC	4	3	2	1
Differential mechanisms of action of abiraterone and MDV3100	4	3	2	1
Results of a Phase III study demonstrating prolonged bone metastasis-free survival with adjuvant denosumab in men with CRPC	4	3	2	1
Cabazitaxel-associated side effects and toxicity in patients with docetaxel-treated mCRPC	4	3	2	1
Emerging data with Alpharadin in patients with symptomatic CRPC and bone metastases	4	3	2	1

Was the activity evidence based, fair, balanced and free from commercial bias?

Yes No

If no, please explain:

Please identify how you will change your practice as a result of completing this activity (select all that apply).

- This activity validated my current practice; no changes will be made
- Create/revise protocols, policies and/or procedures
- Change the management and/or treatment of my patients
- Other (please explain):

If you intend to implement any changes in your practice, please provide 1 or more examples:

The content of this activity matched my current (or potential) scope of practice.

Yes No

If no, please explain:

Please respond to the following learning objectives (LOs) by circling the appropriate selection:

4 = Yes 3 = Will consider 2 = No 1 = Already doing N/M = LO not met N/A = Not applicable

As a result of this activity, I will be able to:

- Use case-based learning, innovative communication strategies and shared clinical insight to provide comprehensive and compassionate oncology care... .4 3 2 1 N/M N/A
- Develop a rational evidence-based approach to the use of bone-targeted therapies for patients with early and advanced-stage prostate cancer.4 3 2 1 N/M N/A
- Counsel patients with metastatic castration-resistant prostate cancer (mCRPC) about the effects of docetaxel and cabazitaxel on quality and quantity of life... .4 3 2 1 N/M N/A
- Recall existing and emerging research information demonstrating the efficacy and tolerability of abiraterone acetate for patients with chemotherapy-pretreated CRPC, and use this information to guide treatment.4 3 2 1 N/M N/A
- Compare and contrast the efficacy, safety and tolerability of evidence-based chemotherapy and immunotherapy for patients with mCRPC.4 3 2 1 N/M N/A
- Evaluate symptoms, tumor burden and pace of disease, and factor these into the integration of sipuleucel-T in the treatment algorithm for mCRPC... .4 3 2 1 N/M N/A
- Synthesize the emerging data and active research evaluating novel agents — including tyrosine kinase inhibitors, radiopharmaceuticals, androgen biosynthesis inhibitors and antiandrogens — in the setting of advanced prostate cancer, and discuss the biologic basis for their clinical activity.4 3 2 1 N/M N/A

EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)

Please describe any clinical situations that you find difficult to manage or resolve that you would like to see addressed in future educational activities:

Would you recommend this activity to a colleague?

- Yes No

If no, please explain:

Additional comments about this activity:

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey.

- Yes, I am willing to participate in a follow-up survey.
No, I am not willing to participate in a follow-up survey.

PART 2 — Please tell us about the faculty and moderator for this educational activity

Table with 4 columns: 4 = Excellent, 3 = Good, 2 = Adequate, 1 = Suboptimal. Rows include Faculty (Matthew R Smith, Stacey B Leibowitz) and Moderator (Neil Love) with ratings for Knowledge of subject matter and Effectiveness as an educator.

Please recommend additional faculty for future activities:

Other comments about the faculty and moderator for this activity:

REQUEST FOR CREDIT — Please print clearly

Name: Specialty:

Professional Designation:

- MD DO PharmD NP RN PA Other

Street Address: Box/Suite:

City, State, Zip:

Telephone: Fax:

Email:

Research To Practice designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

I certify my actual time spent to complete this educational activity to be _____ hour(s).

Signature: Date:

To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at www.ResearchToPractice.com/VPP111/CME.

Visiting Professors

Moderator	Neil Love, MD
Managing Editor and CME Director	Kathryn Ault Ziel, PhD
Scientific Director	Richard Kaderman, PhD
Editorial	Clayton Campbell Gloria Kelly, PhD Jean Pak Margaret Peng
Creative Manager	Fernando Rendina
Graphic Designers	Jessica Benitez Tamara Dabney Silvana Izquierdo
Copy Editing Manager	Kirsten Miller
Senior Production Editor	Aura Herrmann
Copy Editors	Margo Harris David Hill Rosemary Hulce Pat Morrissey/Havlin Alexis Oneca
Production Manager	Tracy Potter
Audio Production	Frank Cesarano
Web Master	John Ribeiro
Multimedia Project Manager	Marie Philemon
Faculty Relations Manager	Melissa Molieri
Continuing Education Administrator for Nursing	Julia W Aucoin, DNS, RN-BC, CNE
Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: DrNeilLove@ResearchToPractice.com Email: CE@ResearchToPractice.com
For CME/CNE Information	

Copyright © 2011 Research To Practice. All rights reserved.

The compact disc, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use

the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Copyright © 2011 Research To Practice.
This activity is supported by educational grants from
Amgen Inc, Astellas Pharma Global Development Inc/Medivation Inc,
Bayer HealthCare Pharmaceuticals, Dendreon Corporation and Sanofi.

Research To Practice®

Sponsored by Research To Practice.

Last review date: December 2011
Release date: December 2011
Expiration date: December 2012
Estimated time to complete: 1.5 hours